Catalyst begins enrolment for second Phase III LMS-003 trial of Firdapse to treat LEMS

US-based biopharmaceutical company Catalyst has begun enrolment for its second Phase III LMS-003 clinical trial of Firdapse to treat Lambert-Eaton myasthenic syndrome (LEMS).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news